SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its...
Related Articles

News
Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences
October 28, 2021
San Francisco Biotechnology Network News
News
Comments Off on Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc… […]

News
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
October 13, 2021
San Francisco Biotechnology Network News
News
Comments Off on Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc… […]